Amicus Therapeutics Appoints Michael C. Diem, MD as Senior Vice President of Business and Corporate Development
October 06 2017 - 7:30AM
Amicus Therapeutics (Nasdaq:FOLD) today announced the appointment
of Michael C. Diem, MD as Senior Vice President of Business and
Corporate Development. He will be responsible for leading all
business and corporate development activities. Dr. Diem will be a
key member of the Amicus senior leadership team reporting to John
F. Crowley, Chairman and Chief Executive Officer of Amicus.
Dr. Diem is a driven business executive and
physician with 12 years of global experience in the pharmaceutical
and biotechnology industries, including leadership roles in
corporate and business development at AstraZeneca and
GlaxoSmithKline (GSK) Rare Diseases. He also has more than nine
years of experience in academic and clinical medicine.
“I am pleased to welcome Dr. Mike Diem to our
senior leadership team at Amicus,” stated Mr. Crowley. “Mike has an
outstanding track record in global business development and
corporate strategy within the biotechnology and pharmaceutical
industries. Mike will be a key leader for Amicus as we evaluate
strategies to enhance our portfolio of leading edge rare disease
medicines and technologies. He will be extremely valuable to Amicus
as we continue to build a top global biotechnology company focused
on devastating rare diseases.”
Prior to joining Amicus, Dr. Diem was Senior
Vice President of Corporate and Business Development at Aevi
Genomic Medicine, where he led all business development and
licensing activities. Previously, Dr. Diem was the Global Head of
Corporate Strategy and Corporate Development for AstraZeneca, where
he was responsible for mergers and acquisitions, externalization
opportunities and divestitures, global opportunities in new areas
of business and the company’s strategic investment activities
(including MedImmune Ventures). Prior to joining AstraZeneca, Dr.
Diem was the Head of Business Development for GSK Rare Diseases
where he led the partnerships, licensing and mergers and
acquisitions activities that formed the Company’s rare disease
portfolio. Earlier he was a partner in GSK’s corporate venture
capital firm, SR One, Limited and served on the boards of numerous
companies. Prior to GSK, Mike was an associate at Frantz Medical
Ventures and practiced medicine for six years.
“I am excited to join the Amicus team during
such an important period of growth and globalization,” said Dr.
Diem. “Amicus is well-positioned for further success with a novel
rare disease portfolio as well as a deep commitment to delivering
meaningful benefits for people living with rare diseases.”
Dr. Diem holds a BA in biological sciences from
Rutgers University, an MD from the Rutgers-Robert Wood Johnson
Medical School and an MBA from the Weatherhead School of Management
at Case Western Reserve University. He completed his medical
training at Duke University Medical Center and is an alumnus of the
Kauffman Fellows Program. Mike is currently a board director at
VenatoRx Pharmaceuticals and is a member of the board of governors
of the Boys and Girls Clubs of Philadelphia.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company
at the forefront of therapies for rare and orphan diseases. The
Company has a robust pipeline of advanced therapies for a broad
range of human genetic diseases. Amicus’ lead programs in
development include the small molecule pharmacological chaperone
migalastat as a monotherapy for Fabry disease, as well as novel
enzyme replacement therapy (ERT) and biologic products for Fabry
disease, Pompe disease, and other rare and devastating
diseases.
Forward-Looking StatementsThis
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
relating to preclinical and clinical development of our product
candidates, the timing and reporting of results from preclinical
studies and clinical trials, the prospects and timing of the
potential regulatory approval of our product candidates,
commercialization plans, financing plans, and the projected cash
position for the Company. The inclusion of forward-looking
statements should not be regarded as a representation by us that
any of our plans will be achieved. Any or all of the
forward-looking statements in this press release may turn out to be
wrong and can be affected by inaccurate assumptions we might make
or by known or unknown risks and uncertainties. For example, with
respect to statements regarding the goals, progress, timing, and
outcomes of discussions with regulatory authorities, and in
particular the potential goals, progress, timing, and results of
preclinical studies and clinical trials, actual results may differ
materially from those set forth in this release due to the risks
and uncertainties inherent in our business, including, without
limitation: the potential that results of clinical or preclinical
studies indicate that the product candidates are unsafe or
ineffective; the potential that it may be difficult to enroll
patients in our clinical trials; the potential that regulatory
authorities, including the FDA, EMA, and PMDA, may not grant or may
delay approval for our product candidates; the potential that we
may not be successful in commercializing Galafold in Europe or our
other product candidates if and when approved; the potential that
preclinical and clinical studies could be delayed because we
identify serious side effects or other safety issues; and the
potential that we will need additional funding to complete all of
our studies. Further, the results of earlier preclinical studies
and/or clinical trials may not be predictive of future results for
any of our product candidates. With respect to statements regarding
projections of the Company's cash position, actual results may
differ based on market factors and the Company's ability to execute
its operational and budget plans. In addition, all forward-looking
statements are subject to other risks detailed in our previous
filings with the SEC and in our Annual Report on Form 10-K for the
year ended December 31, 2016 and Quarterly Report on 10-Q for the
Quarter ended June 30, 2017. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement, and we undertake no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
CONTACTS:
Investors/Media:Amicus
TherapeuticsSara Pellegrino, IRCSenior Director, Investor
Relationsspellegrino@amicusrx.com (609) 662-5044
Media:W2O GroupJennifer
PaganelliMedia Relationsjpaganelli@purecommunications.com (347)
658-8290
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024